Search Results - "de Jong, Alphons J L"
-
1
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab
Published in Arthritis & rheumatology (Hoboken, N.J.) (01-01-2018)“…Objective To evaluate drug survival, effectiveness, pharmacokinetics, immunogenicity, and safety in daily practice after transitioning treatment from original…”
Get full text
Journal Article -
2
Tailored cognitive–behavioral therapy and exercise training for high‐risk patients with fibromyalgia
Published in Arthritis care & research (2010) (01-10-2010)“…Objective The treatment of patients with fibromyalgia (FM), a high‐prevalence chronic pain condition with a high impact on both patients and society, poses a…”
Get full text
Journal Article -
3
Performance of the Dutch SF-36 version 2 as a measure of health-related quality of life in patients with rheumatoid arthritis
Published in Health and quality of life outcomes (08-05-2013)“…The aim of this study was to examine the measurement properties of the Dutch SF-36 version 2 (SF-36v2) health survey in patients with rheumatoid arthritis…”
Get full text
Journal Article -
4
Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial
Published in Pain (Amsterdam) (01-11-2002)“…Recent developments in chronic pain research suggest that effectiveness of cognitive-behavioral therapy (CBT) may be optimized when applying early, customized…”
Get full text
Journal Article -
5
The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study
Published in Rheumatology (Oxford, England) (01-11-2018)“…Abstract Objectives The aim of this study was to identify the factors that play a role for patients with RA when considering dose reduction (i.e. gradual…”
Get full text
Journal Article -
6
Role of cholecystokinin in bombesin-stimulated pancreatic enzyme secretion in conscious rats
Published in Pancreas (01-03-1990)“…Since bombesin is a potent stimulus of cholecystokinin (CCK) secretion, it is assumed that the stimulatory effect of bombesin on pancreatic protein secretion…”
Get full text
Journal Article -
7
A clinical and serological comparison of group A versus non-group A streptococcal reactive arthritis and throat culture negative cases of post-streptococcal reactive arthritis
Published in Annals of the rheumatic diseases (01-07-1999)“…OBJECTIVE To identify clinical and serological differences of patients with reactive arthritis after infection with Lancefield group A β-haemolytic…”
Get full text
Journal Article -
8
Modulation by CR-1409 (lorglumide), a cholecystokinin receptor antagonist, of trypsin inhibitor-enhanced growth of azaserine-induced putative preneoplastic lesions in rat pancreas
Published in Cancer research (Chicago, Ill.) (01-05-1989)“…Feeding of raw soya flour or other trypsin inhibitors such as camostate is a well-established method for promoting growth of (pre)neoplastic foci induced in…”
Get full text
Journal Article -
9
Elemental diet stimulates gallbaldder contraction and secretion of cholecystokinin and pancreatic polypeptide in man
Published in Digestive diseases and sciences (01-01-1987)Get full text
Journal Article -
10
Effect of bombesin and cholecystokinin on plasma immunoreactive trypsin in humans
Published in Pancreas (01-01-1987)“…Since bombesin is a potent stimulus of the release of cholecystokinin (CCK), it has been suggested that the stimulatory effect of bombesin on pancreatic enzyme…”
Get full text
Journal Article -
11
Role of cholecystokinin in bombesin- and meal-stimulated pancreatic polypeptide secretion in dogs
Published in Digestive diseases and sciences (01-09-1990)“…This study was undertaken to delineate the role of cholecystokinin (CCK) in bombesin- and meal-stimulated pancreatic polypeptide (PP) secretion in seven…”
Get full text
Journal Article